Dexmeditomidine vs buprenorphine as an additive to bupivacaine in Spinal anaesthesia
Phase 2
- Registration Number
- CTRI/2023/07/055167
- Lead Sponsor
- DR BABLI DAS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. ASA I and ASA II participants.
2. Patients undergoing orthopaedic lower limb surgeries.
3. Patients undergoing lower umbilical general surgeries.
4. Women undergoing gynaecological surgeries.
5. Age-18-60 years.
6.weight-40kg to 80kg.
7.Height-150 cm and above.
Exclusion Criteria
1.Patientâ??s refusal .
2.Patients with contraindication for specified drugs.
3.Obesity (BMI >30).
4.Pregnant patients.
5.Infection at the site of injection (spinal).
6.Coagulopathy or any other bleeding diasthesis.
7.Severe hypovolemia.
8.Increased intracranial pressure.
9.Structural and functional cardiac abnormalities.
10.Severe spinal deformity.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate & compare the following factors in two groups-intrathecal dexmedetomidine & intrathecal buprenorphine as an adjuvant to hyperbaric bupivacaine in infraumbilical surgeries with respect to: <br/ ><br>1. Sensory & motor blockade -onset & duration. <br/ ><br>Timepoint: Time at which intrathecal drug is administered is T0, followed by T1 at 1min,T2 at 3 min,T3 at 5 min interval......till intraoperative period followed by time required for regaining of sensory and motor sensation in postoperative period.
- Secondary Outcome Measures
Name Time Method Duration of analgesiaTimepoint: perioperative to postoperative period